You are here

Kisqali

Novartis drug helps stop breast cancer’s return in large study

Novartis drug helps stop breast cancer’s return in large study

BioPharma Dive

clinical trials

Flag link:

ASCO preview: Merck's Keytruda, Novartis' Kisqali face their moment of truth in early-stage cancers

ASCO preview: Merck's Keytruda, Novartis' Kisqali face their moment of truth in early-stage cancers

Fierce Pharma

non-small cell lung cancer

early breast cancer

Flag link:

Novartis' Kisqali cuts recurrence risk in early-stage breast cancer

Novartis' Kisqali cuts recurrence risk in early-stage breast cancer

BioSpace

clinical trials

Flag link:

Novartis’ Kisqali Hits Mark in Mid-Stage Breast Cancer Trial

Novartis’ Kisqali Hits Mark in Mid-Stage Breast Cancer Trial

BioSpace

clinical trials

Flag link:

Novartis presents new Kisqali data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer

Novartis presents new Kisqali data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer

Drugs.com

clinical trials

Flag link:

#ASCO21: Novartis keeps building out survival data for Kisqali, hoping to keep the pressure on Pfizer's Ibrance

#ASCO21: Novartis keeps building out survival data for Kisqali, hoping to keep the pressure on Pfizer's Ibrance

Endpoints

Flag link:

SABCS: Novartis touts Kisqali's 5-year breast cancer survival, advantage over Pfizer's Ibrance

SABCS: Novartis touts Kisqali's 5-year breast cancer survival, advantage over Pfizer's Ibrance

Fierce Pharma

Flag link:

Three Breast Cancer Drugs: FDA Warns of Rare but Serious Lung Inflammation

Three Breast Cancer Drugs: FDA Warns of Rare but Serious Lung Inflammation

RAPS.org

Flag link:

Novartis' Kisqali sharpens survival edge with second ph3 win

Novartis' Kisqali sharpens survival edge with second ph3 win

Fierce Pharma

clinical trials

Flag link:

ASCO: Novartis' Kisqali posts first-in-class survival win in younger women

ASCO: Novartis' Kisqali posts first-in-class survival win in younger women

Fierce Pharma

clinical trials

Flag link:

NICE spurns Lilly’s breast cancer drug Verzenio in favor of rivals from Pfizer and Novartisspir

NICE spurns Lilly’s breast cancer drug Verzenio in favor of rivals from Pfizer and Novartisspir

Fierce Pharma

Flag link:

FDA Approves First Cancer Drug Under New Real Time Review Program

FDA Approves First Cancer Drug Under New Real Time Review Program

CP Wire

Real Time Oncology Review

Flag link:

FDA Approves First Cancer Drug Under New Real Time Review Program

Flag link:

ASCO: Novartis makes a case for earlier Kisqali use. Will 'conservative' docs run with it?

ASCO: Novartis makes a case for earlier Kisqali use. Will 'conservative' docs run with it?

Fierce Pharma

metastatic breast cancer

HER2-negative breast cancer

Flag link:

Cancer Space Update: New Regulatory Status for 3 Major Drugs

Cancer Space Update: New Regulatory Status for 3 Major Drugs

Yahoo/Zacks.com

Seattle Genetics

Flag link:

Novartis Gets Second Breakthrough Designation for Kisqali

Novartis Gets Second Breakthrough Designation for Kisqali

Yahoo/Zacks.com

Flag link:

In Young Women, Kisqali Slows Metastatic Breast Cancer And Relieves Symptoms

In Young Women, Kisqali Slows Metastatic Breast Cancer And Relieves Symptoms

Forbes

metastatic breast cancer

Flag link:

Pfizer's Ibrance, Novartis' Kisqali go to battle in England after discounts twin NICE recommendations

Pfizer's Ibrance, Novartis' Kisqali go to battle in England after discounts twin NICE recommendations

Fierce Pharma

Flag link:

Novartis takes fight to Pfizer's Ibrance with new Kisqali data

Novartis takes fight to Pfizer's Ibrance with new Kisqali data

Yahoo/Reuters

Flag link:

Latecomer Verzenio stands out from Ibrance, Kisqali in launch's early days: Lilly

Latecomer Verzenio stands out from Ibrance, Kisqali in launch's early days: Lilly

Fierce Pharma

breast cancer. Eli Lilly

Flag link:

Pages